Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―Hiroaki Kitaoka, Chisato Izumi, Satoshi Yasuda et al.|Circulation Journal|2024Cited by 23
Contemporary clinical characteristics and management patterns in hypertrophic cardiomyopathy: insights from baseline enrolment data in a nationwide prospective Japanese registryToru Kubo, Hiroaki Kitaoka, Miki Tsujiuchi et al.|Heart|2025Cited by 3
Qualitative analysis of experiences, burdens, and needs among patients with hypertrophic cardiomyopathy in JapanYuichiro Maekawa, Hiroaki Kitaoka, Kanako Shimoura et al.|Future Cardiology|2025Cited by 0